The efficacy of COVID-۱۹ vaccination in cystic fibrosis patients: a systematic pulmonary disease review

This systematic review assesses the efficacy and safety of COVID-۱۹ vaccines in individuals with cystic fibrosis (CF). A comprehensive search of major databases between December ۲۰۱۹ and January ۲۰۲۴ identified eight cohort studies including ۱,۳۶۱ CF patients. Studies lacking subgroup analyses specific to CF were excluded, which may limit the generalizability of the findings, particularly for CF lung transplant recipients. Overall, COVID-۱۹ vaccines elicited robust serological responses after the second and third doses, although attenuated antibody levels were noted in lung transplant recipients. Factors influencing humoral response included prior SARS-CoV-۲ infection, age, use of inhaled corticosteroids, and immunosuppressive therapy. Reported vaccine-related adverse events were mostly mild. While breakthrough infections occurred, severe COVID-۱۹ outcomes were rare among vaccinated CF patients. These findings support the immunogenicity and safety of COVID-۱۹ vaccines in the CF population. Nonetheless, individualized vaccination strategies may be warranted for CF lung transplant recipients and patients receiving immunosuppressive treatments. Further research is needed to optimize vaccination approaches and to identify risk factors for breakthrough infections in this high-risk group.